A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
BG-60366-101
Phase 1 other active
Quick answer
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer for EGFR-Mutant Non-Small Cell Lung Cancer is a Phase 1 program (other) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beone Medicines Ireland Limited
- Indication
- EGFR-Mutant Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active